phosphorylcholine has been researched along with praziquantel in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Bouchaud, O; Izri, A | 1 |
Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM; Ramadan, AA | 1 |
Abdel Bary, A; Abdel Salam, SA; Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM | 2 |
4 other study(ies) available for phosphorylcholine and praziquantel
Article | Year |
---|---|
[New antiparasitic drugs].
Topics: Albendazole; Antimalarials; Antiparasitic Agents; Benzimidazoles; Cyclohexanes; Fatty Acids, Unsaturated; Humans; Ivermectin; Nitro Compounds; Phosphorylcholine; Praziquantel; Sesquiterpenes; Thiazoles; Triclabendazole | 2008 |
Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Repositioning; Granuloma; Liver; Mice; Nanocapsules; Nanotechnology; Phosphorylcholine; Praziquantel; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides | 2016 |
Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Combinations; Drug Compounding; Female; Humans; Male; Mice; Nanocapsules; Phosphorylcholine; Praziquantel; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides | 2020 |
Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni.
Topics: Animals; Anthelmintics; Disease Models, Animal; Drug Carriers; Drug Combinations; Granuloma; Lipids; Liver; Male; Mice; Nanocapsules; Nanotechnology; Phosphorylcholine; Praziquantel; Schistosoma mansoni; Schistosomiasis mansoni | 2020 |